elzovantinib
turning point therapeutics
['tpx-0022', 'lung']
nice work from &amp; some lung cancers harbor actionable met tyrosine kinase domain mutations (different from metex14!) that can respond to the met inhibitor tpx-0022. #asco22 
Vivek Subbiah, MD, (@VivekSubbiah) #PrecisionMedicine Expert and Medical Oncologist, takes over our Twitter today to discuss #ASCO22.